The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase II trial of AG-946 in patients with low-risk MDS and anemia
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses the rationale for an upcoming Phase II trial investigating the use of the pyruvate kinase activator AG-946 in patients with low-risk myelodysplastic syndromes (LR-MDS) and anemia. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Geron: Honoraria; Jazz: Honoraria; Abbvie: Honoraria; BMS/Celgene: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Silence Therapeutics: Honoraria; Janssen: Honoraria.
